close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CG Oncology, Inc. - Common stock (NQ:CGON)

68.27 +0.89 (+1.31%)
Delayed Quote Updated: 3:44 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CG Oncology, Inc. - Common stock

< Previous 1 2 3 4 5 Next >
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Monday? ↗
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why ↗
CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder cancer treatment at AUA 2025. 
Via Benzinga
News headline image
3 Analysts Assess CG Oncology: What You Need To Know ↗
 
Via Benzinga
News headline image
Why CG Oncology (CGON) Stock Is Down 9% ↗
CG Oncology shares are trading lower by 9.2% during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock. 
Via Benzinga
News headline image
Demystifying CG Oncology: Insights From 7 Analyst Reviews ↗
 
Via Benzinga
News headline image
These stocks are moving in today's pre-market session ↗
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug ↗
The companies are working on treatments for a form of bladder cancer. 
Via Investor's Business Daily
News headline image
Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
From CG Oncology Inc.
Via GlobeNewswire
News headline image
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Friday's after hours session: top gainers and losers ↗
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Expert Outlook: CG Oncology Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
Late-breaking clinical and first translational data from BOND-003 Cohort C will be presented 
From CG Oncology Inc.
Via GlobeNewswire
News headline image
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug ↗
HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025. 
Via Benzinga
News headline image
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Announces Pricing of Public Offering
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Nasdaq Jumps 300 Points To Record Highs ↗
Stocks are higher this afternoon, after this morning's highly-anticipated CPI report met expectations. 
Via Talk Markets
Topics Stocks / Equities
News headline image
CG Oncology Announces Proposed Public Offering
From CG Oncology Inc.
Via GlobeNewswire
News headline image
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC 
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate ↗
CG Oncology's BOND-003 trial reveals durable efficacy of cretostimogene in NMIBC patients, with median DOR exceeding 27 months and no severe side effects. 
Via Benzinga
News headline image
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.